Evidence map›Paper›PMID 31147814›Full record

ReviewHeart failure reviews2019

Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target.

Antonis S Manolis, Antonis A Manolis, Theodora A Manolis, Helen Melita

Abstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Neurohumoral Activation in Heart Failure.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Sudden Death in Men Versus Women with Heart Failure.Current heart failure reports · 2023
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Antonis S ManolisThird Department of Cardiology, Athens University School of Medicine, Vas. Sofias 114, 115 27, Athens, Greece. asm@otenet.gr.ORCID http://orcid.org/0000-0002-0336-4745
Antonis A ManolisPatras University School of Medicine, Patras, Greece.
Theodora A ManolisRed Cross Hospital, Athens, Greece.
Helen MelitaOnassis Cardiac Surgery Center, Athens, Greece.
University of Patras · GRHellenic Red Cross · GROnassis Cardiac Surgery Center · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) with preserved ejection fraction (HFpEF) represents half of HF patients, who are more likely older, women, and hypertensive. Mortality rates in HFpEF are higher compared with age- and comorbidity-matched non-HF controls and lower than in HF with reduced ejection fraction (HFrEF); the majority (50-70%) are cardiovascular (CV) deaths. Among CV deaths, sudden death (SD) (~ 35%) and HF-death (~ 20%) are the leading cardiac modes of death; however, proportionally, CV deaths, SD, and HF-deaths are lower in HFpEF, while non-CV deaths constitute a higher proportion of deaths in HFpEF (30-40%) than in HFrEF (~ 15%). Importantly, the underlying mechanism of SD has not been clearly elucidated and non-arrhythmic SD may be more prominent in HFpEF than in HFrEF. Furthermore, there is no specific strategy for identifying high-risk patients, probably due to wide heterogeneity in presentation and pathophysiology of HFpEF and a plethora of comorbidities in this population. Thus, the management of HFpEF remains problematic due to paucity of data on the clinical benefits of current therapies, which focus on symptom relief and reduction of HF-hospitalization by controlling fluid retention and managing risk-factors and comorbidities. Matching a specific pathophysiology or mode of death with available and novel therapies may improve outcomes in HFpEF. However, this still remains an elusive target, as we need more information on determinants of SD. Implantable cardioverter-defibrillators (ICDs) have changed the landscape of SD prevention in HFrEF; if ICDs are to be applied to HFpEF, there must be a coordinated effort to identify and select high-risk patients.

Indexed as

AgedAged, 80 and overBiomarkersCause of DeathComorbidityDeath, SuddenDefibrillators, ImplantableFemaleHeart FailureHospitalizationHumansHypertensionMaleMiddle AgedMortalityPrognosisBiomarkersCardiac arrestCardiovascular deathHeart failureHeart failure with preserved ejection fractionLeft ventricular dysfunctionNon-cardiac sudden deathNon-cardiovascular deathSudden cardiac deathSudden deathVentricular fibrillationVentricular tachycardia

Identifiers

PMID31147814
OpenAlexW2946900487

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.